Cannabidiol Explained

Verifiedfields:verified
Watchedfields:verified
Verifiedrevid:457636058
Width:225px
Width2:250px
Tradename:Epidiolex, Epidyolex
Dailymedid:Cannabidiol
Pregnancy Au:B2
Pregnancy Au Comment:[1]
Addiction Liability:None [2]
Routes Of Administration:Inhalation (smoking, vaping), buccal (aerosol spray),[3] [4] oral (solution)[5] [6]
Class:Cannabinoid
Atc Prefix:N03
Atc Suffix:AX24
Legal Au:S4
Legal Br:Synthetic: C3; Oil with <0,2% THC: B1; Oil <30mg/ml THC and <30mg/ml CBD: A3.
Legal Br Comment:[7]
Legal Ca:Unscheduled
Legal De:Anlage III
Legal Nz:Unscheduled
Legal Uk:GSL
Legal Us:Schedule I (pure CBD powder), Schedule V for (Epidiolex) and Unscheduled if derived from hemp in oil form with less than 0.3% D9-THC but may be considered Schedule I if a component of marijuana with more than 0.3% D9-THC.[8] [9]
Legal Eu Comment:[10]
Legal Un:Unscheduled and Rx-only
Legal Status:In general Rx-only
Elimination Half-Life:18–32 hours
Cas Number:13956-29-1
Pubchem:644019
Iuphar Ligand:4150
Drugbank:DB09061
Chemspiderid:559095
Unii:19GBJ60SN5
Kegg:D10915
Chebi:69478
Pdb Ligand:P0T
Synonyms:CBD, cannabidiolum, (−)-cannabidiol[11]
Iupac Name:2-[(1''R'',6''R'')-6-Isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
C:21
H:30
O:2
Smiles:Oc1c(c(O)cc(c1)CCCCC)[C@@H]2\C=C(/CC[C@H]2\C(=C)C)C
Stdinchi:1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1
Stdinchikey:QHMBSVQNZZTUGM-ZWKOTPCHSA-N
Melting Point:66
Boiling Point:160-180
Boiling Notes:[12]
Solubility:Insoluble

Cannabidiol (CBD) is a phytocannabinoid discovered in 1940. It is one of 113 identified cannabinoids in cannabis plants, along with tetrahydrocannabinol (THC), and accounts for up to 40% of the plant's extract., clinical research on CBD included studies related to the treatment of anxiety, addiction, psychosis, movement disorders, and pain, but there is insufficient high-quality evidence that cannabidiol is effective for these conditions.[13] [14] [15] [16] CBD is also sold as a herbal dietary supplement promoted with unproven claims of particular therapeutic effects.

Cannabidiol can be taken internally in multiple ways, including by inhaling cannabis smoke or vapor, oral, and as an aerosol spray into the cheek. It may be supplied as CBD oil containing only CBD as the active ingredient (excluding THC or terpenes), CBD-dominant hemp extract oil, capsules, dried cannabis, or prescription liquid solution.[15] CBD does not have the same psychoactivity as THC,[17] and can modulate the psychoactive effects of THC on the body if both are present.[18] [19] [20] [21] CBD heated to 250–300 °C may partially be converted into THC.[22]

In the United States, the cannabidiol drug Epidiolex was approved by the Food and Drug Administration (FDA) in 2018 for the treatment of two epilepsy disorders.[6] While the 2018 United States Farm Bill removed hemp and hemp extracts (including CBD) from the Controlled Substances Act, the marketing and sale of CBD formulations for medical use or as an ingredient in dietary supplements or manufactured foods remains illegal under FDA regulation, .[23] [24]

Medical uses

Epilepsy

See also: Charlotte's Web (cannabis).

In the United States, the FDA has indicated only one brand of prescription cannabidiol called Epidiolex for the treatment of seizures associated with Dravet syndrome, Lennox–Gastaut syndrome, or tuberous sclerosis complex in people one year of age and older.[25] [26] While Epidiolex treatment is generally well tolerated, it is associated with minor adverse effects, such as gastrointestinal upset, decreased appetite, lethargy, sleepiness and poor sleep quality.[6] [25] [27] [26]

In the European Union, cannabidiol (Epidyolex) is indicated for use as adjunctive therapy of seizures associated with Lennox–Gastaut syndrome or Dravet syndrome, in conjunction with clobazam, for people two years of age and older. In 2020, the label for Epidiolex in the US was expanded to include seizures associated with tuberous sclerosis complex. Epidiolex/Epidyolex is the first prescription formulation of plant-derived cannabidiol approved by regulatory bodies in the US and Europe.[28]

Other uses

Research on other uses for cannabidiol includes several neurological disorders, but the findings have not been confirmed to establish such uses in clinical practice.[29] [14] [15] [30] [31] [32] In October 2019, the FDA issued an advisory warning that the effects of CBD during pregnancy or breastfeeding are unknown, indicating that the safety, doses, interactions with other drugs or foods, and side effects of CBD are not clinically defined, and may pose a risk to the mother and infant.[33]

Many claims are made for the therapeutic benefit of cannabidiol that are not backed by sound evidence. Some claims, such as treatment of cancer, are pseudoscience.[34]

In 2020, the label for Epidiolex in the US was expanded to include treatment of seizures associated with tuberous sclerosis.[35]

Acclaimed for relieving chronic pain, some researchers conclude that the evidence is insufficient to determine the effectiveness of CBD in pain relief, primarily due to the challenging access to pure CBD.[36]

Non-intoxicating effects

Cannabidiol does not appear to have any intoxicating effects[37] such as those caused by ∆-THC in cannabis, but it is under preliminary research for its possible anti-anxiety and anti-psychotic effects.[14] [15] [17] As the legal landscape and understanding about the differences in medical cannabinoids unfolds, experts are working to distinguish "medical cannabis" (with varying degrees of psychotropic effects and deficits in executive function) from "medical CBD therapies", which would commonly present as having a reduced or non-psychoactive side-effect profile.[15] [38]

Various strains of "medical cannabis" are found to have a significant variation in the ratios of CBD-to-THC and are known to contain other non-psychotropic cannabinoids.[39] Any psychoactive cannabis, regardless of its CBD content, is derived from the flower (or bud) of the genus Cannabis. As defined by US federal law, non-psychoactive hemp (also commonly termed "industrial hemp"), regardless of its CBD content, is any part of the cannabis plant, whether growing or not, containing a ∆-tetrahydrocannabinol concentration of no more than 0.3% on a dry-weight basis.[40] In the United States, certain standards are required for legal growing, cultivating, and producing the hemp plant, but there are no federal standards for quality being enforced in the hemp industry. Certain state regulations are in place, but vary state to state.[41] For instance, the Colorado Industrial Hemp Program registers growers of industrial hemp and samples crops to verify that the dry-weight THC concentration does not exceed 0.3%.[40]

Available forms

CBD is present as an active constituent of cannabis, which is used both recreationally and medically.

Nabiximols (brand name Sativex), an oromucosal spray made of a complex botanical mixture containing cannabidiol (CBD), delta-9-tetrahydrocannabinol (THC), and additional cannabinoid and non-cannabinoid constituents from cannabis sativa plants, was approved by Health Canada in 2005, to treat central neuropathic pain in multiple sclerosis, and in 2007, for cancer-related pain.[42] In New Zealand, Sativex is "approved for use as an add-on treatment for symptom improvement in people with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication."[43]

Epidiolex (Epidyolex in Europe) is an orally administered cannabidiol solution.[6] [10] It was approved in 2018 for treatment of two rare forms of childhood epilepsy, Lennox–Gastaut syndrome and Dravet syndrome, and seizures associated with tuberous sclerosis complex.[6] [10] In the US, it is approved in these indications for people one year of age and older.[6]

Side effects

Research indicates that cannabidiol may reduce adverse effects of THC, particularly those causing intoxication and sedation, but only at high doses.[44] Safety studies of cannabidiol showed it is well tolerated, but may cause tiredness, somnolence, sedation, diarrhea, or changes in appetite as common adverse effects with the most common being somnolence and sedation. Side effects of CBD are dose related.[45] Epidiolex documentation lists sleepiness, insomnia and poor quality sleep, decreased appetite, diarrhea, and fatigue.[46]

In November 2019, the FDA issued concerns about the safety of cannabidiol, stating that CBD use has potential to cause liver injury, interfere with the mechanisms of prescription drugs, produce gastrointestinal disorders, or affect alertness and mood. Over 2020–23, the FDA updated its safety concerns about CBD,[47] acknowledging the unknown effects of protracted use, how it affects the developing brain, fetus or infants during breastfeeding, whether it interacts with dietary supplements or prescription drugs, whether male fertility is affected, and its possible side effects, such as drowsiness.[48]

, 1,085 people contacted US poison control centers about CBD-induced illnesses, doubling the number of cases over the 2018 rate and increasing by 9 times the case numbers of 2017.[49] Of cases reported in 2019, more than 33% received medical attention and 46 people were admitted to a hospital intensive care unit, possibly due to exposure to other products, or drug interactions with CBD.

In 2022, the FDA stated that "scientific studies show possible harm to the male reproductive system, including testicular atrophy, harm to the liver, and interactions with certain medications. The FDA has not found adequate information showing how much CBD can be consumed, and for how long, before causing harm. This is particularly true for vulnerable populations like children and those who are pregnant."

Interactions

Laboratory evidence indicated that cannabidiol may reduce THC clearance, increasing plasma concentrations which may raise THC availability to receptors and enhance its effect in a dose-dependent manner.[50] [51] In vitro, cannabidiol inhibited the activity of voltage-dependent sodium and potassium channels, which may affect neural activity.[52] A recent study using X-ray crystallography showed that CBD binds inside the sodium channel pore at a novel site at the interface of the fenestrations and the central hydrophobic cavity of the channel. Binding at this site blocks the transmembrane-spanning sodium ion translocation pathway, providing a molecular mechanism for channel inhibition, which could contribute to a reduced excitability.[53] A small clinical trial reported that CBD partially inhibited the CYP2C-catalyzed hydroxylation of THC to 11-OH-THC.[54] Little is known about potential drug interactions, but CBD mediates a decrease in clobazam metabolism.[55] Work with human liver microsomes shows that cannabidiol inhibits CYP3A5 and CYP3A4 to some degree.[56]

Pharmacology

Pharmacodynamics

In vitro, cannabidiol has low affinity for, and acts as a negative allosteric modulator of the CB cannabinoid receptor[57] [58]

Cannabidiol may be an antagonist of GPR55, a G protein-coupled receptor and putative non-homologous CB3 cannabinoid receptor shown by in vitro studies to be widely distributed in the brain.[59] [60] Cannabidiol may interact with various neurotransmitters, such as serotonin, dopamine, and GABA.[59] [61]

As of 2024, the cellular effects and mechanisms of cannabidiol in vivo are unknown,[6] [10] as research to date has been inconclusive and based on laboratory studies.[62] The anticonvulsant effects provided by cannabidiol (Epidiolex) in people with certain forms of epilepsy do not appear to involve cannabinoid receptors.[6] A possible mechanism for the effects of cannabidiol on seizures is by affecting the neuronal movement of calcium in brain structures involved in the excessive electrical activity of seizures.[10]

Pharmacokinetics

The oral bioavailability of cannabidiol is approximately 6% in fasting state and 36.5—57.3% in fed-state in humans, while its bioavailability via inhalation is 11 to 45% (mean 31%).[63] [64] The oral bioavailability of cannabidiol varies based on several factors such as formulation, dose, and food intake. The elimination half-life of cannabidiol in blood is 56 to 61 hours after oral doses twice per day over 7 days.[6] Based on the pharmacokinetic analysis of long-term dosing of cannabidiol in humans, the terminal elimination half-life is estimated to be >134 h. Cannabidiol is metabolized in the liver as well as in the intestines by cytochrome P450 enzymes.[6] [59]

Chemistry

See also: Conversion of CBD to THC.

At room temperature, cannabidiol is a colorless crystalline solid.[65] In strongly basic media and the presence of air, it is oxidized to Cannabinodiol (CBND) and a quinone called HU-331.[66] Under acidic conditions it cyclizes to THC,[67] which also occurs during pyrolysis,[68] and during smoking.[69] The synthesis of cannabidiol has been accomplished by several research groups.[70] [71] [72]

Biosynthesis

Cannabis produces CBD through the same metabolic pathway as THC, until the next to last step, where CBDA synthase performs catalysis instead of THCA synthase.[73]

Isomerism

See also: Abnormal cannabidiol.

--font-size:small;--> clear:left; width:50%;"+ class="nowrap" Cannabidiol's 7 double bond isomers and their 30 stereoisomers
Formal numbering Terpenoid numbering Number of stereoisomers Natural occurrence Convention on Psychotropic Substances Schedule Structure
Short name Chiral centers Full name Short name Chiral centers
Δ-Cannabidiol 1 and 3 2-(6-isopropenyl-3-methyl-5-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol Δ-Cannabidiol 1 and 3 4 No Unscheduled
Δ-Cannabidiol 1, 3 and 6 2-(6-isopropenyl-3-methyl-4-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol Δ-Cannabidiol 1, 3 and 4 8 No Unscheduled
1 and 6 2-(6-isopropenyl-3-methyl-3-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol Δ-Cannabidiol 3 and 4 4 Yes Unscheduled
Δ-Cannabidiol 1 and 6 2-(6-isopropenyl-3-methylenecyclohex-1-yl)-5-pentyl-1,3-benzenediol Δ-Cannabidiol 3 and 4 4 No Unscheduled
Δ-Cannabidiol1 and 62-(6-isopropenyl-3-methyl-2-cyclohexen-1-yl)-5-pentyl-1,3-benzenediolΔ-Cannabidiol3 and 44YesUnscheduled
Δ-Cannabidiol 3 and 6 2-(6-isopropenyl-3-methyl-1-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol Δ-Cannabidiol 1 and 4 4 No Unscheduled
Δ-Cannabidiol 3 2-(6-isopropenyl-3-methyl-6-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol Δ-Cannabidiol 1 2 No Unscheduled

Pyrolysis

In the typical operating temperature range of e-cigarettes, 25–52% of CBD is transformed into other chemical substances: Δ9-THC, Δ8-THC, cannabinol and cannabichromene as predominant pyrolysates. From a chemical point of view, CBD in e-cigarettes can be considered as a precursor of THC.

Synthetic derivatives

Numerous synthetic derivatives of CBD are known, and have been researched for generally similar applications as CBD itself.[74]

History

Efforts to isolate the active ingredients in cannabis were made in the 19th century. Cannabidiol was studied in 1940 from Minnesota wild hemp[75] and Egyptian Cannabis indica resin.[76] [77] The chemical formula of CBD was proposed from a method for isolating it from wild hemp. Its structure and stereochemistry were determined in 1963.[78]

Plant breeding

Selective breeding of cannabis plants has expanded and diversified as commercial and therapeutic markets develop. Some growers in the US succeeded in lowering the proportion of CBD-to-THC to accommodate customers who preferred varietals that were more mind-altering due to the higher THC and lower CBD content.[79] In the US, hemp is classified by the federal government as cannabis containing no more than 0.3% THC by dry weight. This classification was established in the 2018 Farm Bill and was refined to include hemp-sourced extracts, cannabinoids, and derivatives in the definition of hemp.[80]

Society and culture

Names

Cannabidiol is the generic name of the drug and its .[81]

Foods and beverages

Food and beverage products containing cannabidiol were widely marketed in the United States as early as 2017.[82] Hemp seed ingredients which do not naturally contain THC or CBD (but which may be contaminated with trace amounts on the outside during harvesting) were declared by the US Food and Drug Administration as generally recognized as safe (GRAS) in December 2018. CBD itself has not been declared GRAS, and under US federal law is illegal to sell as a food, dietary supplement, or animal feed. State laws vary considerably as non-medical cannabis and derived products have been legalized in various jurisdictions. Despite once having a promising market, the industry for CBD stalled out during the COVID-19 pandemic beginning in 2020, and, by 2024, it collapsed due to withdrawal of investors, the absence of a FDA ruling on efficacy and safety, inconsistent state-by-state legislation, and consumer ambivalence.[83]

Similar to energy drinks and protein bars which may contain vitamin or herbal additives, food and beverage items can be infused with CBD as an alternative means of ingesting the substance.[83] In the United States, numerous products are marketed as containing CBD, but in reality contain little or none.[84] Some companies marketing CBD-infused food products with claims that are similar to the effects of prescription drugs have received warning letters from the FDA for making unsubstantiated health claims.[85] In February 2019, the New York City Department of Health announced plans to fine restaurants that sell food or drinks containing CBD, beginning in October 2019.[86]

Labeling and advertising

Studies conducted by the FDA from 2014 through 2019 have determined that a majority of CBD products are not accurately labeled with the amount of CBD they contain.[87] For example, a 2017 analysis of cannabidiol content in oil, tincture, or liquid vape products purchased online in the United States showed that 69% were mislabeled, with 43% having higher and 26% having lower content than stated on product labels.[88] [89] In 2020, the FDA conducted a study of 147 CBD products and found that half contained THC.[87] [90]

From 2015 to November 2022, the FDA issued dozens of warning letters to American manufacturers of CBD products for false advertising and illegal interstate marketing of CBD as an unapproved drug to treat diseases, such as cancer, osteoarthritis, symptoms of opioid withdrawal, Alzheimer's disease, and pet disorders.[91] Chemical analysis of CBD products found that many did not contain the levels of CBD claimed in advertising.[91]

In December 2020, the Federal Trade Commission initiated a law enforcement crackdown on American companies marketing CBD products as unapproved drugs.[92] [93] The warning also applied to hemp CBD capsules and oil that were being marketed illegally while not adhering to the federal definition of a dietary supplement.

Sports

See also: Cannabis and sports.

Cannabidiol has been used by professional and amateur athletes across disciplines and countries, with the World Anti-Doping Agency removing CBD from its banned substances list. The United States Anti-Doping Agency and United Kingdom-Anti-Doping Agency do not have anti-CBD policies, with the latter stating that, "CBD is not currently listed on the World Anti-Doping Agency Prohibited List. As a result, it is permitted to use in sport, though the intended benefits are unclear and not backed by clinical evidence. All other cannabinoids (including but not limited to cannabis, hashish, marijuana, and THC) are prohibited in-competition. The intention of the regulations is to prohibit cannabinoids that activate the same receptors in the brain as activated by THC."[94] [95]

In 2019, the cannabis manufacturer Canopy Growth acquired majority ownership of BioSteel Sports Nutrition, which is developing CBD products under endorsement by numerous professional athletes.[96] The National Hockey League Alumni Association began a project with Canopy Growth to determine if CBD or other cannabis products might improve neurological symptoms and quality of life in head-injured players.[96] Some sports leagues have announced sponsorships with CBD companies, such as Major League Baseball (Charlotte's Web) and Ultimate Fighting Championship (Love Hemp).[97] [98] Numerous professional athletes use CBD, primarily for treating pain.[96] [99] [100]

Legal status

Australia

Prescription medicine (Schedule 4) for therapeutic use containing two percent (2.0%) or less of other cannabinoids commonly found in cannabis (such as ∆-THC). A Schedule 4 drug under the SUSMP is a Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by state or territory legislation to prescribe and should be available from a pharmacist on prescription.[101]

In June 2020, the Australian Therapeutic Goods Administration (TGA) published a consultation on a proposal to pave the way to make "low dose" CBD available to consumer/patients via pharmacists only through moving products from Schedule 4 to 3.[102] Any products sold would need to have their safety, quality and efficacy pre-assessed by the TGA and be formally approved for sale (details to be outlined by TGA). They would be made available to over 18s only, with the maximum daily dose of 60mg/day, up to 2% THC finished product allowed, 30-day maximum supply, plant-derived or synthetic. This proposal is based on an initial literature review on the safety of low dose CBD published by the TGA in April 2020.[103] Epidyolex was approved for the adjunctive therapy of seizures associated with Lennox–Gastaut syndrome or with Dravet syndrome in September 2020.

Bulgaria

In 2020, Bulgaria became the first country in the European Union to allow retail sales of food products and supplements containing CBD, despite the ongoing discussion within the EU about the classification of CBD as a novel food.[104] However, there exists a legal gap because of the lack of a legally-permissible minimum amount of THC in the products containing cannabinoids.[105]

Canada

In October 2018, cannabidiol became legal for recreational and medical use by the federal Cannabis Act.[106] [107] [108], CBD products in Canada could only be sold by authorized retailers or federally licensed medical companies, limiting their access to the general public.[109] Nonetheless, with online delivery services and over 2,600 authorized cannabis retail stores, accessibility has steadily increased over time.[110] [111] The Canadian government states that CBD products "are subject to all of the rules and requirements that apply to cannabis under the Cannabis Act and its regulations."[106] It requires "a processing licence to manufacture products containing CBD for sale, no matter what the source of the CBD is, and that CBD and products containing CBD, such as cannabis oil, may only be sold by an authorized retailer or licensed seller of medical CBD."[106] Edible CBD products were scheduled to be permitted for sale in Canada on October 17, 2019, for human consumption.[106]

, it was still illegal to carry cannabis and cannabis-derived products (including products containing CBD) across the Canadian border. If one carries any amount of cannabis for any purpose (including medical), it needs to be declared to the Canada Border Services Agency. Not declaring it is a serious criminal offence.[112]

Czech Republic

As of May 2023, the State Agricultural and Food Inspection of the Czech Republic is putting together broad regulations regarding a ban on CBD products.[113] They will make it illegal to sell products containing cannabidiol and other cannabinoids derived from hemp, as a result of EU Novel Food Regulation. In case of Czech Republic, European Industrial Hemp Association has submitted an official request to the Czech Republic to recognize natural hemp extracts with cannabinoids as traditional food.[114]

European Union

In 2019, the European Commission announced that CBD and other cannabinoids would be classified as "novel foods",[115] meaning that CBD products would require authorization under the EU Novel Food Regulation stating that because "this product was not used as a food or food ingredient before May 15, 1997, before it may be placed on the market in the EU as a food or food ingredient, a safety assessment under the Novel Food Regulation is required."[116] The recommendation – applying to CBD extracts, synthesized CBD, and all CBD products, including CBD oil – was scheduled for a final ruling by the European Commission in March 2019.[115] If approved, manufacturers of CBD products would be required to conduct safety tests and prove safe consumption, indicating that CBD products would not be eligible for legal commerce until at least 2021.[115] In December 2020, the European Commission concluded that CBD should not be considered as drug and can be qualified as food.[117]

Cannabidiol is listed in the EU Cosmetics Ingredient Database (CosIng).[118] However, the listing of an ingredient, assigned with an INCI name, in CosIng does not mean it is to be used in cosmetic products or is approved for such use.[118]

Several industrial hemp varieties can be legally cultivated in Western Europe. A variety such as "Fedora 17" has a cannabinoid profile consistently around 1%, with THC less than 0.3%.[119]

Hong Kong

In 2022, the HKSAR Government proposed a ban on any use of cannabidiol (including for academic research and by medical professionals) within the Hong Kong territory, making Hong Kong the first jurisdiction in the world to have complete prohibition of cannabidiol, starting from February 1, 2023,[120] in part due to the possible presence of THC which is illegal in Hong Kong, according to a research subsidized by the Hong Kong SAR Government.[121] [122] [123]

New Zealand

In 2017, the New Zealand government made changes to the regulations so that restrictions would be removed, which meant a doctor was able to prescribe cannabidiol to patients.[124]

The passing of the Misuse of Drugs (Medicinal Cannabis) Amendment Act in December 2018 means cannabidiol is no longer a controlled drug in New Zealand, but is a prescription medicine under the Medicines Act, with the restriction that "the tetrahydrocannabinols (THCs) and specified substances within the product must not exceed 2 percent of the total CBD, tetrahydrocannabinol (THC) and other specified substances."[125]

Russian Federation

According to a document received in response to an appeal to the Ministry of Internal Affairs of the Russian Federation, measures of state control in the Russian Federation regarding CBD have not been established. However, there is also a response from the Ministry of Health of the Russian Federation indicating that CBD can be considered as an isomer of restricted THC. The "isomer" argument is nonetheless vague, as progesterone, which is freely sold in pharmacies, is also an isomer of THC, all three being .[126] On February 17, 2020, the deputy of the Moscow City Duma Darya Besedina sent an official request to the Prime Minister of the Russian Federation Mikhail Mishustin with a request to eliminate that legal ambiguity by publishing official explanations and, if necessary, making required changes in the corresponding government decree.[127]

Singapore

Singapore allows medical cannabis on a case-by-case basis, usually as a last resort drug. Each case is evaluated by the government, and largely comes in the form of Cannabidiol. However, the country is flexible to what is required for patient treatment, despite having some of the strictest drug laws in the world.

Sweden

Cannabidiol is classified as a medical product in Sweden.[128] However, in July 2019, Supreme Court of Sweden ruled that CBD oil with any concentration of THC falls under the narcotic control laws.[129]

Switzerland

While THC remains illegal, cannabidiol is not subject to the Swiss Narcotic Acts because it does not produce a comparable psychoactive effect.[130] Cannabis products containing less than 1% THC can be sold and purchased legally.[131] [132]

Ukraine

On 7 April 2021 the Ukrainian government legalised use of isolated cannabidiol. Additionally, it approved Nabiximols, a cannabidiol-containing drug, for medical use.[133]

United Kingdom

Cannabidiol, in an oral-mucosal spray formulation combined with delta-9-tetrahydrocannabinol, is a product available by prescription for the relief of severe spasticity due to multiple sclerosis (where other anti-spasmodics have not been effective) in the United Kingdom.[134]

Until 2017, products containing cannabidiol marketed for medical purposes were classed as medicines by the UK regulatory body, the Medicines and Healthcare products Regulatory Agency (MHRA), and could not be marketed without regulatory approval for the medical claims.[135] [136], cannabis oil is legal to possess, buy, and sell in the UK, providing the product does not contain more than 1 milligram of THC and is not advertised as providing a medicinal benefit.[137] Individual police officers and others who are ill-informed of the exact legislature pertaining to cannabidiol, however, may erroneously consider it of dubious legality, reflecting lack of awareness.[138]

In January 2019, the UK Food Standards Agency indicated it would regard CBD products, including CBD oil, as a novel food having no history of use before May 1997, and stated that such products must have authorisation and proven safety before being marketed.[139] The deadline for companies with existing products to submit a full and validated novel foods application with the FSA was 31 March 2021; failure to do so before this date would exclude those companies from selling CBD.[140] New products containing CBD after this deadline would require a fully approved application.[141]

In February 2020, the UK FSA advised vulnerable people, such as pregnant women, breastfeeding mothers, and those already taking medication for other medical concerns not to take CBD. The FSA further recommended that healthy adults should not consume more than 70mg CBD per day.

United Nations

Cannabidiol is scheduled under the Single Convention on Narcotic Drugs as cannabis. International Narcotics Control Board reminds Member States that, at the reconvened sixty-third session of the Commission on Narcotic Drugs, in December 2020, the States members of the Commission rejected the recommendation of WHO that a footnote be added to the entry for cannabis and cannabis resin in Schedule I of the 1961 Convention as amended to exempt from international control preparations containing predominantly CBD and not more than 0.2 per cent of delta-9-THC.[142]

United States

, cannabidiol extracted from marijuana remains a Schedule I Controlled Substance,[143] [144] and is not approved as a prescription drug or dietary supplement or allowed for interstate commerce in the United States.[145] CBD derived from hemp (with 0.3% THC or lower) is legal to sell as a cosmetics ingredient or for other purposes not regulated by the FDA, but cannot be sold under federal law as an ingredient in food, dietary supplement, or animal feed.[146] It is a common misconception that the legal ability to sell hemp (which may contain CBD), and hemp extracts and derivatives (including CBD), makes CBD legal for sale as a supplement or medicine.[147]

In September 2018, the GW Pharmaceuticals drug Epidiolex was placed in Schedule V of the Controlled Substances Act by the Drug Enforcement Administration (DEA),[148] following its approval by the FDA for rare types of childhood epilepsy.[6] It was then removed from the Controlled Substances Act by the DEA in April 2020.[149] Epidiolex is available for prescription use in all 50 states.[150]

In 2013, a CNN program that featured Charlotte's Web cannabis brought increased attention to the use of CBD for the treatment of seizure disorders in children.[151] [152] A number of states passed laws over the next few years to allow the use of low-THC, high-CBD cannabis oil in such situations.[153] These states were in addition to the states that had already legalized cannabis for medical or recreational use. Many states further relaxed their laws regarding CBD following the passage of the 2018 Farm Bill.[154] [155]

The 2014 Farm Bill[156] legalized the sale of "non-viable hemp material" grown within states participating in the Hemp Pilot Program which defined hemp as cannabis containing less than 0.3% of THC.[157] The 2018 Farm Bill removed the hemp plant and all "derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis," including CBD, from the Controlled Substances Act, making them legal to manufacture in the United States.[23] The FDA retains regulatory authority over hemp-derived CBD, while the DEA is not involved in the regulation of legally-compliant hemp and hemp products.[158] The 2018 Farm Bill requires that research and development of CBD for a therapeutic purpose would have to be conducted under notification and reporting to the FDA.

Veterinary use

Research

The number of research projects and scientific publications on cannabidiol and other cannabinoids in pets surged in the late 2010s; nonetheless,, there were no hemp-derived, cannabinoid-rich registered veterinary medicinal products in any of the major regions (see

  1. Legal status
).

In the US and other territories there are, however, numerous veterinary nutraceutical products available over the counter (OTC). The lack of clarity in the regulations governing veterinary hemp food supplements allows for products of questionable quality to flood the market,[159] [160] which may pose a risk to the wellbeing of pets and owners.

To understand better the benefits of CBD and associated compounds for the quality of life of animals, companies specialized in CBD products for animals have been funding research projects.[161] [162] [163] [164]

Canine osteoarthritis

CBD's ability to help regulate the endocannabinoid system[165] [166] [167] and reduce the release of excitatory neurotransmitters could result in a retrograde inhibitory signal that lessens chronic pain responses. Studies in dogs with chronic pain associated with osteoarthritis showed an increase in level of activity in animals receiving CBD-rich food supplements.[168] [169] [170]

Epilepsy

From the results seen in humans with drugs such as Epidiolex and Sativex in scientific studies and reviews,[171] it could be expected that CBD-based products would be helpful to manage seizures in dogs. However, despite the numerous case reports presented by veterinary neurologists supporting the benefits of CBD as adjunctive therapy,, published controlled studies have not shown a statistically significant decrease in the number of seizures across the groups receiving CBD.

Pharmacokinetics

The oral bioavailability of CBD varies greatly across species and it is linked to the presentation and the time of administration.[172] [173] A 24-hour kinetic examination in dogs showed that the absorption of the cannabidiolic acid (CBDA) does occur, and that this molecule is absorbed least twice as well as CBD post oral ingestion.[174]

It was found that the major metabolites of CBD in humans (7-OH-CBD and 7-COOH-CBD) are not prevalent in dogs, while 6-OH-CBD was found to be the primary metabolite in dogs receiving a CBD-enriched cannabis-derived herbal extract,[175] suggesting that canine and human CBD metabolic route might be somewhat different.

Research

, there was little evidence for cannabidiol having a benefits in psychiatric disorders in humans.[13] [176]

In the United States, federal illegality has made it difficult historically to conduct research on CBD.[177]

Further reading

Notes and References

  1. Web site: Epidyolex . Therapeutic Goods Administration (TGA) . 29 September 2020 . 30 September 2020 . October 30, 2021 . https://web.archive.org/web/20211030203454/https://www.tga.gov.au/apm-summary/epidyolex . live .
  2. Web site: Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved Drugs Containing Cannabidiol; Corresponding Change to Permit Requirements. Federal Register, US Federal Government. 28 September 2018 . 10 March 2024.
  3. Itin C, Barasch D, Domb AJ, Hoffman A . Prolonged oral transmucosal delivery of highly lipophilic drug cannabidiol . International Journal of Pharmaceutics . 581 . 119276 . May 2020 . 32243971 . 10.1016/j.ijpharm.2020.119276 . 214785913 .
  4. Itin C, Domb AJ, Hoffman A . A meta-opinion: cannabinoids delivered to oral mucosa by a spray for systemic absorption are rather ingested into gastro-intestinal tract: the influences of fed / fasting states . Expert Opinion on Drug Delivery . 16 . 10 . 1031–1035 . October 2019 . 31393180 . 10.1080/17425247.2019.1653852 . 199505274 .
  5. Web site: Sativex (Cannabidiol/Tetrahydrocannabinol) Bayer Label. bayer.ca. June 28, 2018. January 16, 2021. https://web.archive.org/web/20210116114657/https://omr.bayer.ca/omr/online/sativex-pm-en.pdf. live.
  6. Web site: Epidiolex – cannabidiol solution . DailyMed . 26 August 2020 . 11 September 2020 . February 25, 2021 . https://web.archive.org/web/20210225194817/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec . live .
  7. Web site: Anvisa . Brazilian Health Regulatory Agency . 2023-07-24 . RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230827163149/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 . 2023-08-27 . 2023-08-27 . . pt-BR . 2023-07-25.
  8. https://www.dea.gov/press-releases/2019/08/26/dea-announces-steps-necessary-improve-access-marijuana-research
  9. Web site: 7 U.S. Code § 1639o - Definitions. LII / Legal Information Institute.
  10. Web site: Epidyolex EPAR . European Medicines Agency (EMA) . 24 June 2019 . 11 September 2020 . August 9, 2021 . https://web.archive.org/web/20210809152037/https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex . live . Text was copied from this source which is copyrighted by the European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  11. Web site: cannabidiol (CHEBI:69478). ebi.ac.uk. February 12, 2019. May 12, 2021. https://web.archive.org/web/20210512151607/https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:69478. live.
  12. Web site: Phytocannabinoid Boiling Points . Project CBD . 20 August 2021 . live. https://web.archive.org/web/20190408144226/https://www.projectcbd.org/sites/projectcbd/files/downloads/cannabinoid-boiling-points-thc-cbd.pdf . 2019-04-08 .
  13. Kirkland AE, Fadus MC, Gruber SA, Gray KM, Wilens TE, Squeglia LM . A scoping review of the use of cannabidiol in psychiatric disorders . Psychiatry Research . 308 . 114347 . February 2022 . 34952255 . 8799523 . 10.1016/j.psychres.2021.114347.
  14. Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L . Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis . The Lancet. Psychiatry . 6 . 12 . 995–1010 . December 2019 . 31672337 . 6949116 . 10.1016/S2215-0366(19)30401-8 .
  15. VanDolah HJ, Bauer BA, Mauck KF . Clinicians' Guide to Cannabidiol and Hemp Oils . Mayo Clinic Proceedings . 94 . 9 . 1840–1851 . September 2019 . 31447137 . 10.1016/j.mayocp.2019.01.003 . free .
  16. Prud'homme M, Cata R, Jutras-Aswad D . Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence . Substance Abuse . 9 . 33–38 . January 2015 . 26056464 . 4444130 . 10.4137/SART.S25081 .
  17. Iseger TA, Bossong MG . A systematic review of the antipsychotic properties of cannabidiol in humans . Schizophrenia Research . 162 . 1–3 . 153–161 . March 2015 . 25667194 . 10.1016/j.schres.2015.01.033 . 3745655 .
  18. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS . Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders . Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences . 367 . 1607 . 3364–3378 . December 2012 . 23108553 . 3481531 . 10.1098/rstb.2011.0389 . Review .
  19. Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M . Cannabidiol: State of the art and new challenges for therapeutic applications . Pharmacology & Therapeutics . 175 . 133–150 . July 2017 . 28232276 . 10.1016/j.pharmthera.2017.02.041 .
  20. Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M . Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ-Tetrahydrocannabinol . Neuropsychopharmacology . 43 . 1 . 142–154 . January 2018 . 28875990 . 5719112 . 10.1038/npp.2017.209 .
  21. Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsir Y, Navarro P, Etxebarria N, Usobiaga A . Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes . Journal of Natural Products . 79 . 2 . 324–331 . February 2016 . 26836472 . 10.1021/acs.jnatprod.5b00949 . 1874/350973 . November 27, 2022 . January 5, 2023 . https://web.archive.org/web/20230105025827/https://figshare.com/articles/journal_contribution/Evolution_of_the_Cannabinoid_and_Terpene_Content_during_the_Growth_of_Cannabis_sativa_Plants_from_Different_Chemotypes/5028338 . live .
  22. Czégény Z, Nagy G, Babinszki B, Bajtel Á, Sebestyén Z, Kiss T, Csupor-Löffler B, Tóth B, Csupor D . CBD, a precursor of THC in e-cigarettes . Scientific Reports . 11 . 1 . 8951 . April 2021 . 33903673 . 8076212 . 10.1038/s41598-021-88389-z . 2021NatSR..11.8951C .
  23. Mead A . Legal and Regulatory Issues Governing Cannabis and Cannabis-Derived Products in the United States . Frontiers in Plant Science . 10 . 697 . 2019-06-14 . 31263468 . 6590107 . 10.3389/fpls.2019.00697 . free .
  24. Web site: FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). #2. How does the 2018 Farm Bill define hemp? What does it mean for FDA-regulated products? . US Food and Drug Administration (FDA) . 6 February 2024 . 6 February 2024.
  25. Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, Herkes GK, Farrell M, Degenhardt L . Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence . Journal of Neurology, Neurosurgery, and Psychiatry . 89 . 7 . 741–753 . July 2018 . 29511052 . 10.1136/jnnp-2017-317168 . free . 1959.4/unsworks_50076 . free .
  26. Elliott J, DeJean D, Clifford T, Coyle D, Potter BK, Skidmore B, Alexander C, Repetski AE, Shukla V, McCoy B, Wells GA . Cannabis-based products for pediatric epilepsy: An updated systematic review . Seizure . 75 . 18–22 . February 2020 . 31865133 . 10.1016/j.seizure.2019.12.006 . 208878465 . free .
  27. 2018-06-26 . Cannabis derivative may reduce seizures in some severe drug-resistant epilepsies, but adverse events increase . NIHR Evidence . Plain English summary . 10.3310/signal-000606 . 242083755 . March 15, 2022 . July 24, 2021 . https://web.archive.org/web/20210724033322/https://evidence.nihr.ac.uk/alert/cannabis-derivative-may-reduce-seizures-in-some-severe-drug-resistant-epilepsies-but-adverse-events-increase/ . live .
  28. Web site: Office of the Commissioner. 2020-03-27. FDA Approves First Drug an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy. 2021-05-28. FDA. en. April 23, 2019. https://web.archive.org/web/20190423071605/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611046.htm. live.
  29. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D . Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders . Epilepsia . 55 . 6 . 791–802 . June 2014 . 24854329 . 4707667 . 10.1111/epi.12631 .
  30. Prud'homme M, Cata R, Jutras-Aswad D . Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence . Substance Abuse . 9 . 33–38 . 2015 . 26056464 . 4444130 . 10.4137/SART.S25081 .
  31. Silva TB, Balbino CQ, Weiber AF . The relationship between cannabidiol and psychosis: A review . Annals of Clinical Psychiatry . 27 . 2 . 134–141 . May 2015 . 25954940 .
  32. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR . Cannabidiol as a Potential Treatment for Anxiety Disorders . Neurotherapeutics . 12 . 4 . 825–836 . October 2015 . 26341731 . 4604171 . 10.1007/s13311-015-0387-1 .
  33. Web site: What You Should Know About Using Cannabis, Including CBD, When Pregnant or Breastfeeding . US Food and Drug Administration (FDA) . October 17, 2019 . October 16, 2019 . October 17, 2019 . https://web.archive.org/web/20191017212718/https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding . live .
  34. Web site: . Novella S . Steven Novella . Where Are We With CBD? . 30 September 2020 . October 1, 2020 . August 12, 2021 . https://web.archive.org/web/20210812120451/https://sciencebasedmedicine.org/where-are-we-with-cbd/ . live .
  35. Web site: Office of the Commissioner. 2020-07-31. FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease. 2020-11-25. FDA. en. September 29, 2021. https://web.archive.org/web/20210929230838/https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-drug-containing-active-ingredient-derived-cannabis-treat-seizures-rare. live.
  36. Villanueva MR, Joshaghani N, Villa N, Badla O, Goit R, Saddik SE, Dawood SN, Rabih AM, Niaj A, Raman A, Uprety M, Calero M, Khan S . Efficacy, Safety, and Regulation of Cannabidiol on Chronic Pain: A Systematic Review . Cureus . 14 . 7 . e26913 . July 2022 . 35860716 . 9288157 . 10.7759/cureus.26913 . free .
  37. Kicman A, Toczek M . The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease . International Journal of Molecular Sciences . 21 . 18 . 6740 . September 2020 . 32937917 . 7554803 . 10.3390/ijms21186740 . free .
  38. Sachs J, McGlade E, Yurgelun-Todd D . Safety and Toxicology of Cannabinoids . Neurotherapeutics . 12 . 4 . 735–746 . October 2015 . 26269228 . 4604177 . 10.1007/s13311-015-0380-8 .
  39. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R . Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb . Trends in Pharmacological Sciences . 30 . 10 . 515–527 . October 2009 . 19729208 . 10.1016/j.tips.2009.07.006 .
  40. Web site: 2018. Industrial hemp. September 14, 2018. Department of Agriculture, State of Colorado. August 26, 2018. https://web.archive.org/web/20180826025810/https://www.colorado.gov/pacific/agplants/industrial-hemp. live.
  41. Web site: Cannabinoid Clinical Cannabinoids Research, Effects, and Uses. 2020-10-27. CannabinoidClinical.com. en. June 26, 2021. https://web.archive.org/web/20210626065243/https://www.cannabinoidclinical.com/fda-regulation-cannabinoids. live.
  42. Russo EB . Cannabinoids in the management of difficult to treat pain . Therapeutics and Clinical Risk Management. 4 . 1 . 245–259 . February 2008 . 18728714 . 2503660 . 10.2147/TCRM.S1928 . free .
  43. Web site: Sativex Oromucosal Spray. Medsafe, New Zealand Medicines and Medical Devices Safety Authority. December 19, 2018. April 3, 2019. July 27, 2020. https://web.archive.org/web/20200727071731/https://medsafe.govt.nz/profs/RIss/Sativex/Sativex.asp.
  44. Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, Rehm J, Room R . Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations . American Journal of Public Health . 107 . 8 . e1–e12 . August 2017 . 28644037 . 5508136 . 10.2105/AJPH.2017.303818 . free.
  45. Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP . Cannabidiol Adverse Effects and Toxicity . Current Neuropharmacology . 17 . 10 . 974–989 . 2019-09-13 . 31161980 . 10.2174/1570159x17666190603171901 . Bentham Science Publishers Ltd. . 7052834 .
  46. Web site: Cannabidiol (CBD): MedlinePlus Supplements. 2021-01-15. medlineplus.gov. en. October 20, 2021. https://web.archive.org/web/20211020055709/https://medlineplus.gov/druginfo/natural/1439.html. live.
  47. Web site: FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). US Food and Drug Administration (FDA) . 29 October 2023 . 28 September 2023.
  48. Web site: Hahn SM . Stephen Hahn (oncologist) . FDA Advances Work Related to Cannabidiol Products with Focus on Protecting Public Health, Providing Market Clarity . US Food and Drug Administration . 6 March 2020 . 5 March 2020 . September 29, 2021 . https://web.archive.org/web/20210929230626/https://www.fda.gov/news-events/press-announcements/fda-advances-work-related-cannabidiol-products-focus-protecting-public-health-providing-market . live .
  49. Web site: September 30, 2019. Cannabidiol (CBD). October 17, 2019. American Association of Poison Control Centers. October 17, 2019. https://web.archive.org/web/20191017161650/https://aapcc.org/CBD-Alert. live.
  50. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ . Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain . Drug Metabolism and Disposition . 23 . 8 . 825–831 . August 1995 . 7493549 .
  51. Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, Gunasekaran N, Karl T, Long LE, Huang XF, Liu K, Arnold JC, McGregor IS . Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats . Psychopharmacology . 218 . 2 . 443–457 . November 2011 . 21667074 . 10.1007/s00213-011-2342-0 . 6240926 .
  52. Ghovanloo MR, Shuart NG, Mezeyova J, Dean RA, Ruben PC, Goodchild SJ . Inhibitory effects of cannabidiol on voltage-dependent sodium currents . The Journal of Biological Chemistry . 293 . 43 . 16546–16558 . October 2018 . 30219789 . 6204917 . 10.1074/jbc.RA118.004929 . free .
  53. Sait LG, Sula A, Ghovanloo MR, Hollingworth D, Ruben PC, Wallace BA . Cannabidiol interactions with voltage-gated sodium channels . eLife . 9 . October 2020 . 33089780 . 7641581 . 10.7554/eLife.58593 . free .
  54. Nadulski T, Pragst F, Weinberg G, Roser P, Schnelle M, Fronk EM, Stadelmann AM . Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract . Therapeutic Drug Monitoring . 27 . 6 . 799–810 . December 2005 . 16306858 . 10.1097/01.ftd.0000177223.19294.5c . 12979224 .
  55. Lucas CJ, Galettis P, Schneider J . The pharmacokinetics and the pharmacodynamics of cannabinoids . British Journal of Clinical Pharmacology . 84 . 11 . 2477–2482 . November 2018 . 30001569 . 6177698 . 10.1111/bcp.13710 .
  56. Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K . Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety . Life Sciences . 88 . 15–16 . 730–736 . April 2011 . 21356216 . 10.1016/j.lfs.2011.02.017 .
  57. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor . 2015 . 4621983 . British Journal of Pharmacology . 172 . 20 . 4790–4805 . 10.1111/bph.13250 . 26218440 . Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM .
  58. Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor . Medicinal Research Reviews. 2016 . 5397374 . 37 . 3 . 441–474 . 10.1002/med.21418 . 27879006 . Nguyen T, Li JX, Thomas BF, Wiley JL, Kenakin TP, Zhang Y .
  59. Web site: 14 July 2023 . Cannabidiol . 12 February 2024 . Drugs.com.
  60. Gray RA, Whalley BJ . The proposed mechanisms of action of CBD in epilepsy . Epileptic Disorders . 22 . S1 . 10–15 . January 2020 . 10.1684/epd.2020.1135 . 32053110. free .
  61. Martínez-Aguirre C, et al . Cannabidiol Acts at 5-HT1A Receptors in the Human Brain: Relevance for Treating Temporal Lobe Epilepsy . Front. Behav. Neurosci. . 14 . December 2020 . 611278 . 33384591 . 10.3389/fnbeh.2020.611278 . 7770178 . free .
  62. Schouten M, Dalle S, Mantini D, Koppo K . Cannabidiol and brain function: current knowledge and future perspectives . Frontiers in Pharmacology . 14 . 1328885 . 2023 . 38288087 . 10823027 . 10.3389/fphar.2023.1328885. free.
  63. Kolli AR, Hoeng J . Cannabidiol Bioavailability Is Nonmonotonic with a Long Terminal Elimination Half-Life: A Pharmacokinetic Modeling-Based Analysis . Cannabis and Cannabinoid Research . April 2024 . 38624257 . 10.1089/can.2023.0214 .
  64. O'Sullivan SE, Jensen SS, Kolli AR, Nikolajsen GN, Bruun HZ, Hoeng J . Strategies to Improve Cannabidiol Bioavailability and Drug Delivery . Pharmaceuticals . 17 . 2 . 244 . February 2024 . 38399459 . 10892205 . 10.3390/ph17020244 . MDPI . free .
  65. Jones PG, Falvello L, Kennard O, Sheldrick GM, Mechoulam R . Cannabidiol . Acta Crystallogr. B . 33 . 3211–3214 . 1977 . 10.1107/S0567740877010577 . 10 . 1977AcCrB..33.3211J . free .
  66. Mechoulam R, Ben-Zvi Z, Gaoni Y . Hashish – 13. On the nature of the Beam test . Tetrahedron . 24 . 16 . 5615–5624 . August 1968 . 5732891 . 10.1016/0040-4020(68)88159-1 .
  67. Gaoni Y, Mechoulam R . Hashish – VII The isomerization of cannabidiol to tetrahydrocannabinols . Tetrahedron . 22 . 4 . 1481–1488 . 1966 . 10.1016/S0040-4020(01)99446-3 .
  68. Küppers FJ, Bercht CA, Salemink CA, Lousberg RC, Terlouw JK, Heerma W . Cannabis – XV: Pyrolysis of cannabidiol. Structure elucidation of four pyrolytic products . Tetrahedron. 31. 13–14. 1513–1516. 10.1016/0040-4020(75)87002-5. 1975 .
  69. Quarles W, Ellman G, Jones R . Toxicology of marijuana: conditions for conversion of cannabidiol to THC upon smoking . Clinical Toxicology . 6 . 2 . 211–216 . 1973 . 4715204 . 10.3109/15563657308990520 .
  70. Petrzilka T, Haefliger W, Sikemeier C, Ohloff G, Eschenmoser A . [Synthesis and optical rotation of the (-)-cannabidiols] . Helvetica Chimica Acta . 50 . 2 . 719–723 . March 1967 . 5587099 . 10.1002/hlca.19670500235 .
  71. Gaoni Y, Mechoulam R . Boron trifluoride etherate on alumuna – a modified Lewis acid reagent. An improved synthesis of cannabidiol . Tetrahedron Letters . 26 . 8 . 1083–1086 . 1985 . 10.1016/S0040-4039(00)98518-6 .
  72. Kobayashi Y, Takeuchi A, Wang YG . Synthesis of cannabidiols via alkenylation of cyclohexenyl monoacetate . Organic Letters . 8 . 13 . 2699–2702 . June 2006 . 16774235 . 10.1021/ol060692h .
  73. Marks MD, Tian L, Wenger JP, Omburo SN, Soto-Fuentes W, He J, Gang DR, Weiblen GD, Dixon RA . Identification of candidate genes affecting Delta9-tetrahydrocannabinol biosynthesis in Cannabis sativa . Journal of Experimental Botany . 60 . 13 . 3715–3726 . 2009 . 19581347 . 2736886 . 10.1093/jxb/erp210 .
  74. Nelson KM, Bisson J, Singh G, Graham JG, Chen SN, Friesen JB, Dahlin JL, Niemitz M, Walters MA, Pauli GF . The Essential Medicinal Chemistry of Cannabidiol (CBD) . Journal of Medicinal Chemistry . 63 . 21 . 12137–12155 . November 2020 . 32804502 . 10.1021/acs.jmedchem.0c00724 . 7666069 .
  75. Adams R, Hunt M, Clark JH . Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp.. Journal of the American Chemical Society . 62 . 1 . 1940 . 0002-7863 . 10.1021/ja01858a058 . 196–200.
  76. Jacob A, Todd AR . Cannabidiol and cannabol, constituents of Cannabis indica resin . Nature . 145 . 3670 . 1940 . 0028-0836 . 10.1038/145350a0 . 350. 1940Natur.145..350J . 4106662 . free .
  77. Work TS, Bergel F, Todd AR . The active principles of Cannabis indica resin. I . The Biochemical Journal . 33 . 1 . 123–127 . January 1939 . 16746878 . 1264344 . 10.1042/bj0330123 .
  78. Mechoulam R, Shvo Y . Hashish. I. The structure of cannabidiol . Tetrahedron . 19 . 12 . 2073–2078 . December 1963 . 5879214 . 10.1016/0040-4020(63)85022-x .
  79. News: Romney L. September 13, 2012. On the frontier of medical pot to treat boy's epilepsy. Los Angeles Times. April 16, 2020. October 21, 2018. https://web.archive.org/web/20181021190630/http://articles.latimes.com/2012/sep/13/local/la-me-customized-marijuana-20120914. live.
  80. Web site: 7 U.S. Code § 5940 – Legitimacy of industrial hemp research. 2018-11-27. LII / Legal Information Institute. December 22, 2020. https://web.archive.org/web/20201222033600/https://www.law.cornell.edu/uscode/text/7/5940. live.
  81. 2016. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information. 30. 2. 241. February 18, 2023. February 5, 2018. https://web.archive.org/web/20180205073351/http://www.who.int/medicines/publications/druginformation/innlists/PL115.pdf. live.
  82. News: Billboard featuring hemp leaf raises questions about new beverage for sale in Cincinnati WLWT5. 2017-09-29. WLWT5. 2017-09-29. December 26, 2020. https://web.archive.org/web/20201226180044/https://www.wlwt.com/article/billboard-featuring-hemp-leaf-raises-questions-about-new-beverage-for-sale-in-cincinnati/12662040. live.
  83. News: Creswell, Julie . Companies were big on CBD. Not anymore . 25 March 2024 . The New York Times . 28 February 2024.
  84. Web site: Warning Letters and Test Results for Cannabidiol-Related Products . US Food and Drug Administration (FDA) . January 2, 2018 . November 2, 2017 . January 26, 2018 . https://web.archive.org/web/20180126014518/https://www.fda.gov/NewsEvents/PublicHealthFocus/ucm484109.htm . live .
  85. Web site: Companies Marketing CBD Products Be Warned: FDA Is Watching . Lexology . Fox A, Ravitz JR, Leongini EM, Malkin BJ . November 20, 2017 . 2017-12-14 . August 3, 2020 . https://web.archive.org/web/20200803230044/https://www.lexology.com/library/detail.aspx?g=fe616692-9e03-43bc-9149-8aa1a35a9d9e . live .
  86. News: New York City plans to fine restaurants using CBD in food and drinks. La Vito A, Franck T. 2019-02-15. CNBC. 2019-02-19. November 7, 2020. https://web.archive.org/web/20201107233204/https://www.cnbc.com/2019/02/15/new-york-may-start-fining-restaurants-for-using-weed-related-cbd-.html. live.
  87. Web site: Sampling Study of the Current Cannabidiol Marketplace to Determine the Extent That Products are Mislabeled or Adulterated Report in Response to Further Consolidated Appropriations Act, 2020 . United States Food and Drug Administration . July 2020 . January 30, 2021 . June 23, 2021 . https://web.archive.org/web/20210623193320/https://hempindustrydaily.com/wp-content/uploads/2020/07/CBD-Marketplace-Sampling_RTC_FY20_Final.pdf . live .
  88. Bonn-Miller MO, Loflin MJ, Thomas BF, Marcu JP, Hyke T, Vandrey R . Labeling Accuracy of Cannabidiol Extracts Sold Online . JAMA . 318 . 17 . 1708–1709 . November 2017 . 29114823 . 5818782 . 10.1001/jama.2017.11909 .
  89. News: MacKeen D. October 16, 2019. Scam or Not: What Are the Benefits of CBD?. The New York Times. October 17, 2019 . October 16, 2019. https://web.archive.org/web/20191016221458/https://www.nytimes.com/2019/10/16/style/self-care/cbd-oil-benefits.html. live.
  90. Evans DG . Medical Fraud, Mislabeling, Contamination: All Common in CBD Products . Missouri Medicine . 117 . 5 . 394–399 . 2020 . 33311737 . 7723146 .
  91. Web site: FDA Warns Companies for Illegally Selling Food and Beverage Products that Contain CBD . US Food and Drug Administration . 23 November 2022 . 21 November 2022 . These companies are selling CBD containing products that people may confuse for traditional foods or beverages which may result in unintentional consumption or overconsumption of CBD. CBD-containing products in forms that are appealing to children, such as gummies, hard candies and cookies, are especially concerning. . November 23, 2022 . https://web.archive.org/web/20221123224059/https://www.fda.gov/food/cfsan-constituent-updates/fda-warns-companies-illegally-selling-food-and-beverage-products-contain-cbd . live .
  92. Web site: FTC Announces Crackdown on Deceptively Marketed CBD Products. US Federal Trade Commission (FTC). 12 January 2021. 17 December 2020. June 22, 2021. https://web.archive.org/web/20210622223827/https://www.ftc.gov/news-events/press-releases/2020/12/ftc-announces-crackdown-deceptively-marketed-cbd-products. live.
  93. Web site: Ashley DD, Engle MK . Warning letter: Rooted Apothecary LLC . Office of Compliance, Center for Drug Evaluation and Research, US Food and Drug Administration; US Federal Trade Commission . October 23, 2019 . October 22, 2019 . December 12, 2019 . https://web.archive.org/web/20191212105951/https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rooted-apothecary-llc-585312-10102019 . live .
  94. Web site: Athlete Advisory Note: Cannabidiol (CBD). United Kingdom Anti-Doping Agency. 2019-10-09. October 9, 2019. https://web.archive.org/web/20191009110419/https://www.ukad.org.uk/athlete-advisory-note-cannabidiol-cbd. live.
  95. Web site: Athletes: 6 things to know about cannabidiol . US Anti-Doping Agency . 17 February 2020 . 23 October 2018 . October 11, 2021 . https://web.archive.org/web/20211011032929/https://www.usada.org/spirit-of-sport/education/six-things-know-about-cannabidiol/ . live .
  96. News: Donna S . Canopy cannabis company buys ex-NHL player's sports nutrition business . 17 February 2020 . CTV Business . The Canadian Press . 2 October 2019 . BioSteel's brand ambassadors also include well-known athletes across major sports leagues in North America, which could be beneficial as the company's attempt to push regulated CBD nutrition products into the mainstream health and wellness segments . November 26, 2020 . https://web.archive.org/web/20201126082519/https://www.ctvnews.ca/business/canopy-cannabis-company-buys-ex-nhl-player-s-sports-nutrition-business-1.4620013 . live .
  97. October 12, 2022 . Major League Baseball, pioneering CBD brand Charlotte's Web strike groundbreaking deal . Major League Baseball.
  98. March 18, 2021 . UFC Names Love Hemp Official Global CBD Partner . Ultimate Fighting Championship.
  99. News: Loudin A . As more pro athletes use cannabis for aches and pain, the more they run afoul of rules . 17 February 2020 . The Washington Post . 7 December 2019 . November 24, 2020 . https://web.archive.org/web/20201124094701/https://www.washingtonpost.com/health/as-more-pro-athletes-use-cannabis-for-aches-and-pain-the-more-they-run-afoul-of-rules/2019/12/06/7dbd82fc-00c7-11ea-8bab-0fc209e065a8_story.html . live .
  100. Harrison S . Lots of athletes say CBD Is a better painkiller. Is It? . 17 February 2020 . Wired . 28 September 2019 . July 12, 2021 . https://web.archive.org/web/20210712160248/https://www.wired.com/story/lots-of-athletes-say-cbd-is-a-better-painkiller-is-it/ . live .
  101. Web site: Poisons Standard June 2017 . Legislation.gov.au . December 4, 2016 . December 13, 2020 . https://web.archive.org/web/20201213060305/https://www.legislation.gov.au/Details/F2017L00605/ . live .
  102. Web site: Australian Government Department of Health Therapeutic Goods Administration. 2020-04-24. Consultation: Proposed amendments to the Poisons Standard – Joint ACMS/ACCS meetings, June 2020. 2020-11-25. Therapeutic Goods Administration (TGA). en. May 11, 2021. https://web.archive.org/web/20210511053302/https://www.tga.gov.au/consultation-invitation/consultation-proposed-amendments-poisons-standard-joint-acmsaccs-meetings-june-2020. live.
  103. Web site: Safety of low dose cannabidiol . April 2020 . Therapeutic Goods Administration . Government of Australia . November 25, 2020 . September 7, 2021 . https://web.archive.org/web/20210907175547/https://www.tga.gov.au/sites/default/files/review-safety-low-dose-cannabidiol.pdf . live .
  104. Web site: This EU country has become the first to allow free sale Of CBD. Hasse J. Forbes. 2020-02-21. October 6, 2021. https://web.archive.org/web/20211006020147/https://www.forbes.com/sites/javierhasse/2019/05/23/this-eu-country-has-apparently-become-the-first-to-allow-free-sale-of-cbd/. live.
  105. Web site: Todorova SE. Growing cannabis in Bulgaria: Legal but still stigmatised. 2020-09-03. Lexology. July 29, 2019. April 11, 2021. https://web.archive.org/web/20210411021658/https://www.lexology.com/library/detail.aspx?g=b18a928d-6437-4544-b834-12cd169bd9b2. live.
  106. Web site: Cannabidiol (CBD) . Government of Canada . October 11, 2019 . August 13, 2019 . September 18, 2019 . https://web.archive.org/web/20190918124123/https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/about/cannabidiol.html#a4 . live .
  107. Web site: Health products containing cannabis or for use with cannabis: Guidance for the Cannabis Act, the Food and Drugs Act, and related regulations . Government of Canada . October 19, 2018 . July 11, 2018 . October 19, 2018 . https://web.archive.org/web/20181019121912/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/guidance-cannabis-act-food-and-drugs-act-related-regulations/document.html . live .
  108. Web site: Cannabis Legalization and Regulation. Government of Canada. Department of Justice, Electronic Communications. June 20, 2018. November 24, 2018. August 24, 2021. https://web.archive.org/web/20210824170353/https://www.justice.gc.ca/eng/cj-jp/cannabis/. live.
  109. Web site: 'It should be available': Natural health food stores hope to cash in on CBD craze . CBC News . October 11, 2019 . August 6, 2019 . October 12, 2019 . https://web.archive.org/web/20191012060444/https://www.cbc.ca/news/canada/ottawa/natural-health-food-retailers-cannabis-cbd-market-1.5237911 . live .
  110. Web site: Number of cannabis stores in Canada as of June 2021, by region . Conway J . Statista . 2021-09-17 . 2022-05-02 . May 2, 2022 . https://web.archive.org/web/20220502201541/https://www.statista.com/statistics/1035996/number-of-cannabis-stores-by-region-canada/ . live .
  111. News: Armstrong M . Cannabis store openings in Canada only slightly affected the number of users . The Conversation . 2021-10-13 . 2022-05-02 . May 2, 2022 . https://web.archive.org/web/20220502201541/https://theconversation.com/amp/cannabis-store-openings-in-canada-only-slightly-affected-the-number-of-users-169055 . live .
  112. Web site: Canada Health . 2018-06-20 . Cannabis and Canadian borders . 2020-09-03 . aem . August 14, 2021 . https://web.archive.org/web/20210814083741/https://www.canada.ca/en/services/health/campaigns/cannabis/border.html . live .
  113. Web site: Ministerstvo zemědělství informuje o chystaném zákazu uvádění na trh produktů obsahujících kanabidiol (CBD) a jiné kanabinoidy (eAGRI) . 2023-05-08 . eagri.cz . cs.
  114. Web site: Milosz F . 2023-05-06 . EIHA reacts about CBD and hemp extracts . https://web.archive.org/web/20230506175817/https://cannabizeu.com/eiha-reacts-about-cbd-and-hemp-extracts/ . 6 May 2023 . 2023-05-08 . CannabizEU . en-US.
  115. Web site: Updated EC ruling for CBD classes supplement ingredient as Novel Food . NutraIngredients.com, William Reed Business Media Ltd. . Chu W . January 31, 2019 . January 1, 2019 . November 1, 2021 . https://web.archive.org/web/20211101213517/https://www.nutraingredients.com/Article/2019/01/31/Updated-EC-ruling-for-CBD-classes-supplement-ingredient-as-Novel-Food . live .
  116. Web site: Cannabinoids, searched in the EU Novel food catalogue (v.1.1) . European Commission . February 1, 2019 . January 1, 2019 . April 3, 2019 . https://web.archive.org/web/20190403221542/http://ec.europa.eu/food/safety/novel_food/catalogue/search/public/index.cfm . live .
  117. Web site: 2020-12-02. European Commission reverses course, says CBD should not be regulated as a narcotic. 2020-12-04. Hemp Industry Daily. en-US. October 21, 2021. https://web.archive.org/web/20211021163656/https://hempindustrydaily.com/breaking-european-commission-reverses-course-says-cbd-should-not-be-regulated-as-a-narcotic/. live.
  118. Web site: CosIng – Cosmetics – Cannabidiol. European Commission. December 4, 2016. January 13, 2019. https://web.archive.org/web/20190113182333/http://ec.europa.eu/growth/tools-databases/cosing/index.cfm?fuseaction=search.details_v2&id=93486. live.
  119. Fournier G, Beherec O, Bertucelli S . Intérêt du rapport Δ-9-THC / CBD dans le contrôle des cultures de chanvre industriel . The advantage of the Δ-9-THC / CBD ratio in the control of industrial hemp crops . fr . Annales de Toxicologie Analytique . 15 . 4 . 250–259 . 2003 . 10.1051/ata/2003003 . free .
  120. Web site: Orders to amend Dangerous Drugs Ordinance and Control of Chemicals Ordinance to be gazetted on October 21 and cannabidiol to become dangerous drug . Hong Kong SAR Government . October 20, 2022 . October 20, 2022 . https://web.archive.org/web/20221020134136/https://www.info.gov.hk/gia/general/202210/20/P2022102000492.htm?fontSize=1 . live .
  121. Web site: 2022-06-11 . What you need to know about a proposed ban on CBD products in Hong Kong . 2022-09-25 . South China Morning Post . en . September 25, 2022 . https://web.archive.org/web/20220925034831/https://www.scmp.com/news/hong-kong/health-environment/article/3181288/hong-kong-has-proposed-banning-cbd-products . live .
  122. Web site: Leung H . 2022-08-21 . Hong Kong's zero-tolerance approach to drugs leaves budding CBD industry high and dry . 2022-09-25 . Hong Kong Free Press HKFP . en-GB . April 20, 2023 . https://web.archive.org/web/20230420184936/https://hongkongfp.com/2022/08/21/hong-kongs-zero-tolerance-approach-to-drugs-leaves-budding-cbd-industry-high-and-dry/ . live .
  123. Web site: Legislative Council Panel on Security . 7 June 2022 . Government of Hong Kong . Proposed Control of Cannabidiol through Legislation . October 24, 2022 . September 28, 2022 . https://web.archive.org/web/20220928210959/https://www.legco.gov.hk/yr2022/english/panels/se/papers/se20220607cb2-380-3-e.pdf . live .
  124. Web site: Doctors now able to prescribe cannabidiol. June 2, 2017. June 2, 2017. radionz.co.nz. June 1, 2017. https://web.archive.org/web/20170601230111/http://www.radionz.co.nz/news/political/332137/doctors-now-able-to-prescribe-cannabidiol. live.
  125. Web site: CBD products. March 10, 2019. www.health.govt.nz. February 4, 2019. https://web.archive.org/web/20190204024704/https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicines-control/medicinal-cannabis/cbd-products. live.
  126. Web site: Является ли вещество CBD (каннабидиол) разрешенным к использованию на территории России? – Правовед.RU. February 19, 2021. November 1, 2021. https://web.archive.org/web/20211101213628/https://pravoved.ru/question/2412784/. live.
  127. Web site: Журнал переписки депутата Бесединой. February 19, 2021. February 19, 2021. https://web.archive.org/web/20210219064618/https://besedina.moscow/messaging/242. live.
  128. Web site: CBD products should follow the drug laws. Swedish Medical Products Agency. April 4, 2018. July 31, 2018. July 24, 2018. https://web.archive.org/web/20180724032251/https://lakemedelsverket.se/Alla-nyheter/NYHETER---2018/CBD-produkter-ska-folja-lakemedelslagen/. live.
  129. Web site: Arnold M. 2019-07-30. Sweden Joins Italy In Path To Defining CBD Oil Regulations. 2020-09-03. Cannabis Industry Journal. November 8, 2020. https://web.archive.org/web/20201108021557/https://cannabisindustryjournal.com/news_article/sweden-joins-italy-in-path-to-defining-cbd-oil-regulations/. live.
  130. Web site: Cannabis: What is allowed, what is not allowed in Switzerland? – www.ch.ch. 2020-09-03. www.ch.ch. January 21, 2021. https://web.archive.org/web/20210121154628/https://www.ch.ch/en/safety-and-justice/police/cannabis/. live.
  131. Web site: Vischer AG. Kohler S, Benz AS, Pruschy D. Trends in the Swiss Cannabis Regulation Lexology. 2020-09-03. www.lexology.com. April 11, 2019. January 17, 2021. https://web.archive.org/web/20210117113611/https://www.lexology.com/library/detail.aspx?g=f50473b1-32a3-43a1-a05a-acafc5c937f6. live.
  132. Web site: Cannabis à faible teneur en THC et CBD. dead. https://web.archive.org/web/20170326123332/https://www.bag.admin.ch/bag/fr/home/themen/mensch-gesundheit/sucht/cannabis/thc-armer-cannabis-cbd.html. March 26, 2017. May 20, 2017. BAG.Admin.ch. fr.
  133. News: В Україні легалізували використання медичного канабісу, але не всього . Cross D . УП.Життя (UP.Life) . 9 April 2021 . Ukrainian . Ukraine has legalized the use of medical cannabis, but not all of it . April 10, 2021 . April 9, 2021 . https://web.archive.org/web/20210409202156/https://life.pravda.com.ua/health/2021/04/9/244505/ . live .
  134. Web site: Sativex Oromucosal Spray – Summary of Product Characteristics (SmPC) . (emc) . 25 August 2020 . 11 September 2020 . February 4, 2021 . https://web.archive.org/web/20210204162637/https://www.medicines.org.uk/emc/product/602/smpc . live .
  135. News: MHRA statement on products containing Cannabidiol (CBD). Gov.uk. December 14, 2016. December 14, 2016. May 10, 2019. https://web.archive.org/web/20190510061128/https://www.gov.uk/government/news/mhra-statement-on-products-containing-cannabidiol-cbd. live.
  136. Web site: UK Classifies CBD Oil as a Medicinal Ingredient. 2020-09-03. BuyCBD.net. November 1, 2021. https://web.archive.org/web/20211101213519/https://www.buycbd.net/blog/uk-classifies-cbd-oil-as-a-medicinal-ingredient/. live.
  137. News: Stallworth J. Drug licensing factsheet: cannabis, CBD and other cannabinoids. The Home Office. December 10, 2020. January 17, 2021. https://web.archive.org/web/20210117213102/https://www.gov.uk/government/publications/cannabis-cbd-and-other-cannabinoids-drug-licensing-factsheet/drug-licensing-factsheet-cannabis-cbd-and-other-cannabinoids#the-exempted-product-definition---regulation-2-of-the-mdr-2001. live.
  138. Ukaegbu O, Smith J, Hall D, Frain T, Abbasian C. Staff awareness of the use of cannabidiol (CBD): a trust-wide survey study in the UK. Journal of Cannabis Research. 2021 Dec;3(1):1-0.
  139. Web site: Gunn L, Haigh L . British watchdog deems CBD a novel food, seeks to curtail sale on UK market . Nutrition Insight, CNS Media BV . January 29, 2019 . January 1, 2019 . https://web.archive.org/web/20190202042806/https://www.nutritioninsight.com/news/british-watchdog-deems-cbd-a-novel-food-seeks-to-ban-sale-on-uk-market.html . February 2, 2019 .
  140. Web site: 24 September 2020. Cannabidiol (CBD) guidance – Business guidance on cannabidiol (CBD) as a novel food. 8 December 2020. UK Food Standards Agency. October 30, 2021. https://web.archive.org/web/20211030090033/https://www.food.gov.uk/business-guidance/cannabidiol-cbd. live.
  141. Web site: Marsat N. 2020-07-07. CBD and Novel Foods regulation in the UK: regulation then and now. 2020-12-10. Health Europa. en-GB. October 6, 2020. https://web.archive.org/web/20201006014147/https://www.healtheuropa.eu/cbd-and-novel-foods-regulation-in-the-uk-regulation-then-and-now/101187/. live.
  142. Web site: Reports published by the International Narcotics Control Board for 2021 . December 1, 2022 . November 30, 2022 . https://web.archive.org/web/20221130103840/https://www.incb.org/documents/Publications/AnnualReports/AR2021/Annual_Report/E_INCB_2021_1_eng.pdf . live .
  143. Mead A . The legal status of cannabis (marijuana) and cannabidiol (CBD) under US law . Epilepsy & Behavior . 70 . Pt B . 288–291 . May 2017 . 28169144 . 10.1016/j.yebeh.2016.11.021 . free .
  144. Web site: Text – H.R.2 – 115th Congress (2017-2018): Agriculture Improvement Act of 2018. Conaway KM. 2018-12-20. Congress.gov. 2019-05-01. October 6, 2021. https://web.archive.org/web/20211006230238/https://www.congress.gov/bill/115th-congress/house-bill/2/text. live.
  145. Web site: What You Need to Know (And What We're Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD . US Food and Drug Administration . 23 June 2022 . 5 March 2020 . October 22, 2021 . https://web.archive.org/web/20211022185821/https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis . live .
  146. Web site: . FDA: No CBD in dietary supplements or foods for now, but let's talk . Bellamy J . May 9, 2019 . June 15, 2019 . August 17, 2020 . https://web.archive.org/web/20200817142121/https://sciencebasedmedicine.org/fda-no-cbd-in-dietary-supplements-or-foods-for-now-but-lets-talk/ . live .
  147. Web site: Abernethy A, Schiller L . FDA is Committed to Sound, Science-based Policy on CBD . US Food and Drug Administration (FDA) . October 17, 2019 . July 17, 2019 . November 14, 2019 . https://web.archive.org/web/20191114232749/https://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-and-experts/fda-committed-sound-science-based-policy-cbd . live .
  148. News: DEA reschedules Epidiolex, marijuana-derived drug, paving the way for it to hit the market . CNBC . September 27, 2018 . October 3, 2018 . April 26, 2021 . https://web.archive.org/web/20210426202908/https://www.cnbc.com/2018/09/27/dea-schedules-epidiolex-allowing-gw-pharma-to-start-selling-the-drug.html . live .
  149. News: Wood S . DEA relaxes rules for the only federally approved drug derived from marijuana . April 23, 2023 . The Philadelphia Inquirer . April 6, 2020 . https://web.archive.org/web/20200609035500/https://www.inquirer.com/business/weed/epidiolex-cbd-cannabidiol-gw-pharma-roark-dea-fda-20200406.html . June 9, 2020.
  150. News: Tinker B . First FDA-approved cannabis-based drug now available in the US . April 23, 2023 . CNN . November 2, 2018.
  151. Maa E, Figi P . The case for medical marijuana in epilepsy . Epilepsia . 55 . 6 . 783–786 . June 2014 . 24854149 . 10.1111/epi.12610 . 4849160 . free .
  152. Web site: Saundra Y . Marijuana stops child's severe seizures . CNN . August 7, 2013 . May 14, 2018 . May 14, 2018 . https://web.archive.org/web/20180514144200/https://www.cnn.com/2013/08/07/health/charlotte-child-medical-marijuana/index.html . live .
  153. Web site: State Medical Marijuana Laws. National Conference of State Legislatures. April 27, 2018. May 14, 2018. December 11, 2018. https://web.archive.org/web/20181211125951/http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. live.
  154. News: Schuman B, Fisher J, Radke B, Faldetta G . A Survey of State CBD & Hemp Regulation Since The 2018 Farm Bill . April 24, 2023 . Cannabis Industry Journal . October 22, 2020.
  155. News: Gebhart F . The Evolution of the CBD Regulatory Landscape . April 24, 2023 . Drug Topics Journal . September 13, 2022.
  156. Web site: The 2014 Farm Bill. thefarmbill.com. 2018-11-27. October 30, 2021. https://web.archive.org/web/20211030111724/https://www.thefarmbill.com/the-bill. live.
  157. News: No, CBD Is Not 'Legal in All 50 States'. Zhang M. Forbes. 2018-11-27. December 5, 2020. https://web.archive.org/web/20201205235942/https://www.forbes.com/sites/monazhang/2018/04/05/no-cbd-is-not-legal-in-all-50-states/. live.
  158. Web site: DEA announces steps necessary to improve access to marijuana research . United States Drug Enforcement Administration . October 18, 2019 . August 26, 2019 . October 18, 2019 . https://web.archive.org/web/20191018222642/https://www.dea.gov/press-releases/2019/08/26/dea-announces-steps-necessary-improve-access-marijuana-research . live .
  159. Web site: FDA warns company marketing unapproved cannabidiol products with unsubstantiated claims to treat cancer, Alzheimer's disease, opioid withdrawal, pain and pet anxiety . US Food and Drug Administration (FDA) . July 24, 2019 . July 23, 2019 . Unlike drugs approved by the FDA, the manufacturing process of these products has not been subject to FDA review as part of the drug approval process, and there has been no FDA evaluation of whether these products are effective for their intended use, what the proper dosage is, how they could interact with FDA-approved drugs, or whether they have dangerous side effects or other safety concerns. . August 14, 2019 . https://web.archive.org/web/20190814014310/https://www.fda.gov/news-events/press-announcements/fda-warns-company-marketing-unapproved-cannabidiol-products-unsubstantiated-claims-treat-cancer . live .
  160. Wakshlag JJ, Cital S, Eaton SJ, Prussin R, Hudalla C . Cannabinoid, Terpene, and Heavy Metal Analysis of 29 Over-the-Counter Commercial Veterinary Hemp Supplements . Veterinary Medicine: Research and Reports . 11 . 45–55 . 2020-04-15 . 32346530 . 7169471 . 10.2147/vmrr.s248712 . free .
  161. McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL . Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy . Journal of the American Veterinary Medical Association . 254 . 11 . 1301–1308 . June 2019 . 31067185 . 10.2460/javma.254.11.1301 . 148569810 .
  162. Verrico CD, Wesson S, Konduri V, Hofferek CJ, Vazquez-Perez J, Blair E, Dunner K, Salimpour P, Decker WK, Halpert MM . A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain . Pain . 161 . 9 . 2191–2202 . September 2020 . 32345916 . 7584779 . 10.1097/j.pain.0000000000001896 .
  163. Mogi C, Fukuyama T. Cannabidiol as a potential anti-epileptic dietary supplement in dogs with suspected epilepsy: three case reports. Pet Behaviour Science. 2019. 7. 11–16. 10.21071/pbs.v0i7. 2445-2874. free. December 17, 2020. September 3, 2020. https://web.archive.org/web/20200903190519/https://www.uco.es/ucopress/ojs/index.php/pet/issue/view/960. live.
  164. Wakshlag JJ, Schwark WS, Deabold KA, Talsma BN, Cital S, Lyubimov A, Iqbal A, Zakharov A . Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract . Frontiers in Veterinary Science . 7 . 505 . 2020-09-04 . 33102539 . 7498943 . 10.3389/fvets.2020.00505 . free .
  165. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TP . Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS . Proceedings of the National Academy of Sciences of the United States of America . 100 . 18 . 10529–10533 . September 2003 . 12917492 . 193595 . 10.1073/pnas.1834309100 . 2003PNAS..10010529I . free .
  166. Hohmann AG, Farthing JN, Zvonok AM, Makriyannis A . Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin . The Journal of Pharmacology and Experimental Therapeutics . 308 . 2 . 446–453 . February 2004 . 14610224 . 10.1124/jpet.103.060079 . 17663780 .
  167. Book: Jung KM, Piomelli D . Cannabinoids and Endocannabinoids. 2015 . Neuroscience in the 21st Century. 1–31. Pfaff DW, Volkow ND . New York. Springer New York. en. 10.1007/978-1-4614-6434-1_136-1. 978-1461464341 .
  168. Gamble LJ, Boesch JM, Frye CW, Schwark WS, Mann S, Wolfe L, Brown H, Berthelsen ES, Wakshlag JJ . 2018-07-23 . Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs . Frontiers in Veterinary Science . 5 . 165 . 10.3389/fvets.2018.00165 . 6065210 . 30083539 . free.
  169. Brioschi FA, Di Cesare F, Gioeni D, Rabbogliatti V, Ferrari F, D'Urso ES, Amari M, Ravasio G . August 2020 . Oral Transmucosal Cannabidiol Oil Formulation as Part of a Multimodal Analgesic Regimen: Effects on Pain Relief and Quality of Life Improvement in Dogs Affected by Spontaneous Osteoarthritis . Animals . 10 . 9 . 1505 . 10.3390/ani10091505 . 7552307 . 32858828 . free.
  170. Kogan L, Hellyer P, Downing R . 2020 . Hemp Oil Extract to Treat Canine Osteoarthritis-Related Pain: A Pilot Study . live . Journal of the American Holistic Veterinary Medical Association . 58 . 35–45 . https://web.archive.org/web/20211101213526/https://www.researchgate.net/publication/339698157_The_Use_of_Cannabidiol-Rich_Hemp_Oil_Extract_to_Treat_Canine_Osteoarthritis-Related_Pain_A_Pilot_Study . November 1, 2021 . December 17, 2020.
  171. Book: Russo E . Handbook of psychotropic herbs: a scientific analysis of herbal remedies for psychiatric conditions. 2001. Haworth Herbal Press. 0789007185. New York. 43810871.
  172. Deabold KA, Schwark WS, Wolf L, Wakshlag JJ . October 2019 . Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats . Animals . 9 . 10 . 832 . 10.3390/ani9100832 . 6826847 . 31635105 . free.
  173. Vaughn D, Kulpa J, Paulionis L . Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs . Frontiers in Veterinary Science . 7 . 51 . 2020-02-11 . 32118071 . 7029731 . 10.3389/fvets.2020.00051 . free .
  174. Della Rocca G, Di Salvo A . Hemp in Veterinary Medicine: From Feed to Drug . Frontiers in Veterinary Science . 7 . 387 . 2020-07-28 . 32850997 . 7399642 . 10.3389/fvets.2020.00387 . free .
  175. Chicoine A, Illing K, Vuong S, Pinto KR, Alcorn J, Cosford K . Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs . Frontiers in Veterinary Science . 7 . 583404 . 2020-09-29 . 33134364 . 7550466 . 10.3389/fvets.2020.583404 . free .
  176. Hoch E, Niemann D, von Keller R, Schneider M, Friemel CM, Preuss UW, Hasan A, Pogarell O . How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review . European Archives of Psychiatry and Clinical Neuroscience . 269 . 1 . 87–105 . February 2019 . 30706168 . 6595000 . 10.1007/s00406-019-00984-4 .
  177. News: Sanders L . The CBD boom is way ahead of the science . April 24, 2023 . Science News . March 27, 2019.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cannabidiol".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.